0000000000528183

AUTHOR

Randy S. Morris

showing 2 related works from this author

Altered Regulation of Insulin-Like Growth Factor Binding Protein-I in Patients With Polycystic Ovary Syndrome

1995

Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5–8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of …

medicine.medical_specialty030219 obstetrics & reproductive medicineInsulinmedicine.medical_treatmentGrowth factorSerum insulinObstetrics and GynecologyOctreotideBiologyPolycystic ovaryInsulin-like growth factor-binding protein03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicinebiology.proteinIn patientSecretion030217 neurology & neurosurgerymedicine.drugJournal of the Society for Gynecologic Investigation
researchProduct

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct